Interní Med. 2006; 8(2): 76-78

The occurrence of Helicobacter pylori infection and gastroesophageal reflux disease

MUDr. Karel Lukáš CSc
Gastroenterologické centrum VFN, IV. interní klinika VFN a 1. LF UK Praha

Prevalence of Helicobacter pylori in patients with gastroesophageal reflux disease does not differ from a general population. The bacteria are present neither in normal epithelium nor in epithelium changed by inflammation because under normal conditions no gastric epithelium is found in esophagus. The increased prevalence of gastroesophageal reflux disease during recent years is associated with a decrease of Helicobacter pylori infection leading to speculations that Helicobacter pylori might be beneficial. The gastric inflammation caused by Helicobacter pylori infection decreases a gastric acid secretion that may explain why the intensity of reflux is not so intense and severe esophagitis does not occur. Results of epidemiologic studies differ, some of them show a protective effect against esophageal reflux disease and others show that the effect is not clinically relevant. The presence of Helicobacter pylori has no effect on percentage of relapses of the reflux esophagitis after a short-term treatment with omeprazol. Patients with duodenal and gastric ulcer undergoing an eradication therapy of Helicobacter pylori infection do not have a higher incidence of reflux esophagitis. Inflammatory changes in cardia („carditis“) are found in mucosa under the Z line in patients with reflux disease. These changes may be caused by Helicobacter pylori infection as well. Barrett’s esophagus with high degree dysplasia and adenocarcinoma of esophagus are significantly more frequent in patients who do not have Helicobacter pylori infection. Current opinions on eradication of Helicobacter pylori infection are not in esophageal reflux disease unanimous. Eradication is recommended in cases with concomitant peptic ulcer disease.

Keywords: Key words: Helicobacter pylori, esophageal reflux disease, esophagitis, carditis, Barrett’s esophagus, proton pump inhibitors.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáš K. The occurrence of Helicobacter pylori infection and gastroesophageal reflux disease. Interní Med. 2006;8(2):76-78.
Download citation

References

  1. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: New threats of the old friend. Ann Clin Microbiol Antimicrob. 2005; 4: 1. Go to original source... Go to PubMed...
  2. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut, 37, 1995; 492-498. Go to original source... Go to PubMed...
  3. Blaser MJ. Not all Helicobacter pylori strains are cured equal: should all be eliminated? Lancet, 349, 1997; 35: 1020-1022. Go to original source... Go to PubMed...
  4. Bowrey DJ, Clark GWB, Williams GT. Patterns of gastritis in patients with gastro-oesophageal reflux disease. Gut, 45, 1999; 6: 798-803. Go to original source... Go to PubMed...
  5. Calleja JL, Suarez M, De Tejada AH, Navarro A. Pantogerd Group: Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole. Dig.Dis.Sci., 2005, Mar; 50 (3): 432-439. Go to original source... Go to PubMed...
  6. Clark GWB. Inflammation and metaplasia in the transitional epitehelium of the gastroesophageal junction: a new marker for gastroesophageal reflux disease. Sixth World Congress of the International Society for Diseases of the Oesophagus, 1995.
  7. Csendes A, Smok G, Burdiles P, et al., ,Carditis" an objective histological marker for pathologic gastroesophageal reflux disease. Dis.Esophagus, 11, 1998; 2: 101-105. Go to original source... Go to PubMed...
  8. Delaney B, McColl K. Helicobacter pylori and gastroesophageal reflux disease. Aliment Pharmacol.Ther. 22, 2005; (Suppl. 1): 32-40. Go to original source... Go to PubMed...
  9. Dent J. Helicobacter pylori and reflux disease. In: pH-Hp - Decisive, New Evidence. Astra Symposium, Praha, 28. 6. 1997, 32-33.
  10. Fukuchi T, Ashida K, Yamashita H, Kiyota N, Tsukamoto R, Takahashi H, Ito D, Nagamatsu R. Influence of cure of Helicobacter pylori infection on gastric acidity and gastroesophageal reflux: study by 24-h pH monitoring in patients with gastric or duodenal ulcer. J. Gastroenterol. 2005 Apr; 40 (4): 350-360. Go to original source... Go to PubMed...
  11. Genta RM. Giving carditis back to heart. Gut, 45, 1999; 793-794. Go to original source... Go to PubMed...
  12. Gisbert JP, Pique JM. Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease. Med. Clin., 2005 May 14; 124 (18): 697-709. Go to original source... Go to PubMed...
  13. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or Ranitidine in Long-Term Treatment of Reflux Esophagitis. Gastroenterol., 107, 1994; 1305-1311. Go to original source... Go to PubMed...
  14. Chen YY, Antonioli DA, Spechler SJ, Zeroogian JM, Goyal RK, Wang HH. Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Mod.Pathol., 11, 1998; 10: 950-958.
  15. Kahrilas PJ, Wu S, Lin S, Pouderoux P. Attenuation of esophageal shortening during peristalsis with hiatus hernia. Gastroenterology, 109, 1995; 1818-1828. Go to original source... Go to PubMed...
  16. Kuipers EJ, Lundell L, Klinkenberg-Knoll E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med., 334, 1996; 16: 1018-1022. Go to original source... Go to PubMed...
  17. Kupcinskas L, Malfertheiner P. Helicobacter pylori and non-malignant diseases. Helicobacter. 2005; 10 (Suppl 1): 26-33. Go to original source... Go to PubMed...
  18. Lukáš K, Mandys V. Mareček P, Vernerová Z, Šmejkalová K, Horníková J. Výskyt, ,žaludeční karditidy" u pacientů se symptomy refluxní choroby. Čes. a slov. gastroenterol. A Hepatol., 55, 2001; 3: 92-98.
  19. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, Meyer-Sabellek W, Junghard O, Stolte M. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in nonerosive GORD: report from the ProGORD study. Gut. 2005 Jun; 54 (6): 746-751. Go to original source... Go to PubMed...
  20. McNamara D, O´Morain C. Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation. Gut, 45, 1999; (Suppl. 1): 13-17. Go to original source... Go to PubMed...
  21. Megraud F. Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr. Infect. Dis. Rep., 2005 Mar; 7 (2): 115-120. Go to original source... Go to PubMed...
  22. Moayyedi P. Should we test for Helicobacter pylori before treating gastroesophageal reflux disease? Can J Gastroenterol. 2005 Jul; 19 (7): 425-427. Go to original source... Go to PubMed...
  23. Moss SF, Arnold R, Tytgat GNJ, Spechler SJ, Delle Fave G, Rosin D, Jensen RT, Modlin IM. Consensus Statement for Management of Gastroesophageal Reflux Disease. J. Clin. Gastroenterol., 27, 1998; 1: 6-12. Go to original source... Go to PubMed...
  24. Nandurkar S, Talley NJ. Barrett´s Esophagus: The Long and Short of It. Amer. J. Gastroenterol., 94, 1999; 1: 30-40. Go to original source...
  25. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett´s oesophagus. Gut, 1977; 40: 9-13. Go to original source... Go to PubMed...
  26. Öberg S, Peters JH, Nigro JJ, et al. Helicobacter pylori Is Not Associated With Manifestation of Gastroesophageal Reflux Disease. Arch.Surg., 134, 1999; 722-726. Go to original source... Go to PubMed...
  27. Peek RM Jr, Vaezi MF, Falk GW, et al. Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int.J.Cancer, 82, 1999; 4, 520-524. Go to original source...
  28. Refluxní choroba jícnu - Standardy české gastroenterologické společnosti. Pracovní skupina České gastroenterologické společnosti pro problematiku refluxní choroby jícnu, Praha, 2000.
  29. Riddell RH. The Biopsy Diagnosis of Gastroesophageal Reflux Disease,, ,Carditis", and Barrett´s Esophagus, and Sequelae of Therapy. Am. J. Surg. Pathol., 20, 1996; (Suppl. 1): 31. Go to original source... Go to PubMed...
  30. Sakata H, Fujimoto K. Barrett's esophagus and Helicobacter pylori. Nippon Rinsho. 2005 Aug; 63 (8): 1383-1386.
  31. Spechler SJ. The role of gastric carditis in metaplasia at the gastroesophageal junction. Gastroenterology, 117, 1999; 1: 218-228. Go to original source... Go to PubMed...
  32. Vakil N. Dyspepsia and GERD: breaking the rules. Am. J. Gastroenterol. 2005 Jul;100(7):1477-88. Go to original source... Go to PubMed...
  33. Voutilainen M, Färkkilä M, Juhola M, et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut, 45, 1999; 5: 644-648. Go to original source... Go to PubMed...
  34. Werdmuller BFM, Loffeld RJLF. Helicobater pylori Infection Has No Role in the Pathogenesis of Reflux Esophagitis. Dig. Dis. Sci., 42, 1997; 1: 103-105. Go to original source... Go to PubMed...
  35. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett´s esophagus, Barrett´s dysplasia, and Barrett´s carcinoma. Amer. J. Gastroenterol., 95, 2000; 387-394. Go to original source... Go to PubMed...
  36. Wu JC, Sung JJ, Ng EK, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am.J.Gastroenterol., 94, 1999; 7: 1790-1794. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.